Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.
Fiche publication
Date publication
janvier 2021
Journal
American journal of obstetrics and gynecology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FAIVRE Laurence
Tous les auteurs :
Schrijver LH, Antoniou AC, Olsson H, Mooij TM, Roos-Blom MJ, Azarang L, Adlard J, Ahmed M, Barrowdale D, Davidson R, Donaldson A, Eeles R, Evans DG, Frost D, Henderson A, Izatt L, Ong KR, Bonadona V, Coupier I, Faivre L, Fricker JP, Gesta P, VAN Engelen K, Jager A, Menko FH, Mourits MJE, Singer CF, Tan YY, Foretova L, Navratilova M, Schmutzler RK, Ellberg C, Gerdes AM, Caldes T, Simard J, Olah E, Jakubowska A, Rantala J, Osorio A, Hopper JL, Phillips KA, Milne RL, Terry MB, NoguÈs C, Engel C, Kast K, Goldgar DE, Leeuwen FEV, Easton DF, Andrieu N, Rookus MA,
Lien Pubmed
Résumé
Ovarian cancer risk in BRCA1 and BRCA2 mutation carriers has been shown to decrease with longer duration of oral contraceptive preparations (OCPs) use. While the effects of OCPs in the general population are well established (∼50% reduction), the estimated risk reduction in mutation carriers is much less precise due to potential bias and small sample sizes. In addition, only a few studies have examined the associations between duration of use, time since last use, starting age, and calendar year of start with risk of ovarian cancer.
Mots clés
BRCA1, BRCA2, Ovarian cancer, epidemiology, multivariate, observational, oral contraceptives, retrospective, risk, survival bias
Référence
Am J Obstet Gynecol. 2021 Jan 22;: